CD274 and neoplasm: Immune checkpoint blockade, particularly targeting the PD-1/PD-L1 axis, has shown clinical utility in hepatocellular carcinoma (HCC), but its efficacy is often constrained by insufficient T cell infiltration and an immunosuppressive tumor microenvironment.